Brainmarker-I differentially predicts remission to various attention-deficit/hyperactivity disorder treatments: A blinded discovery, transfer and validation study

Contains fulltext : 247442.pdf (Publisher’s version ) (Open Access) Background: Attention-deficit/hyperactivity disorder is characterized by neurobiological heterogeneity, possibly explaining why not all patients benefit from a given treatment. As a means to select the right treatment (stratification), biomarkers may aid in personalizing treatment prescription, thereby increasing remission rates. Methods: The biomarker in this study was developed in a heterogeneous clinical sample (N=4249), and first applied to two large transfer datasets, a priori stratifying young males (